Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
In today's exhilarating announcement, ImmuPharma PLC, a distinguished name in the realm of drug discovery and development, has taken a giant leap in its ongoing journey of innovation. The promising progress in its late-stage clinical programme for Chronic Idiopathic Demyelinating Polyneuropathy (CIDP) further cements ImmuPharma's commitment to advancing healthcare, and presents an array of compelling reasons for continuing engagement with this dynamic company.
1. Expansion of the P140 Platform's Scope:
ImmuPharma's P140 peptide platform stands as a testament to its innovative spirit. Already lauded for its effectiveness in addressing Systemic Lupus Erythematosus (SLE), the recent positive feedback from the FDA has extended the platform's applicability to CIDP as well. This broadening of P140's therapeutic reach reinforces the company's ability to navigate new territories in autoimmune and inflammatory diseases.
2. Tapping into a High-Need Market:
ImmuPharma's foray into the CIDP market represents a well-calculated stride into a domain characterised by significant unmet medical needs. With global sales projected to reach an impressive US$2.7bn by 2029, the company's impending Phase 2/3 adaptive clinical trial for CIDP aligns ImmuPharma with a potential growth trajectory that is both meaningful and substantial.
3. Pursuit of Orphan Drug Status:
ImmuPharma's intention to apply for Orphan Drug status alongside the Investigational New Drug (IND) application is a clear signal of its long-term strategic planning. Attaining this status would afford the company seven years of market exclusivity following approval, a valuable opportunity to fully leverage the potential of the CIDP market.
4. Navigating the Regulatory Waters with Ease:
Today's positive guidance from the FDA instils confidence in ImmuPharma's regulatory acumen. It is indicative of a potential smooth sailing through future regulatory processes, which bodes well for the company's ability to expedite its clinical development plans.
5. Stability through a Dual-Therapeutic Approach:
ImmuPharma’s strategic concentration is not singular. The company maintains a strong commitment to its Lupus programme, with a Phase 2/3 clinical trial for Lupus patients also scheduled to commence in H2 2023. This concurrent advancement in two crucial therapeutic areas imbues the company, and those closely engaged with it, with a sense of stability often elusive in the biotechnology sector.
In sum, ImmuPharma's recent progress demonstrates its robust potential for growth and resilience. The company’s diverse therapeutic portfolio, underscored by positive regulatory feedback and a clear strategic vision, provides ample reasons for sustained engagement. ImmuPharma’s unfolding narrative promises to be a journey of relentless innovation and steadfast commitment to improving patient care.
Disclaimer: This is a personal perspective, not investment advice. Please consult a financial
Oscar22 - 'fraid I only got as far as this part of your post before I fell off my chair laughing: "ImmuPharma PLC, a distinguished name in the realm of drug discovery and development"
Even I laughed at that post Oscar lol are you the broker doing the placing that’s my worry
Oscar22
Your somewhat exuberant language adds some charm to your write up.... thanks for your latest update summary
Lordloadsoflolly, your superficial approach to the complex domain of biotech investing becomes quite apparent with each comment you share. It seems you struggle to fully grasp the profound potential held by revolutionary entities such as ImmuPharma. It's unfortunate that this skewed perspective only serves to distort the dialogue. Surely, brevity has its place, but when it mirrors a deficiency of comprehension and foresight, it does a disservice to the conversation. Undoubtedly, laughter is a welcome relief, but in the realm of investing, it is in-depth understanding and detailed analysis that hold the key to success. I implore you to broaden your knowledge base of the sector before resorting to dismissive, surface-level remarks. As this is my final response to you, it is clear that we operate on vastly divergent plains, and my vision evidently extends far beyond yours.
Oscar22, As a long term investor, I must commend you on your detailed and insightful analysis of ImmuPharma. Your substantial contribution significantly elevates the quality of discourse on this investment board. It's refreshing to see such in-depth understanding and thoughtfulness shared here, it is disappointing to see so many lousy and ignorant comments in this board like Lambo or Lord's. I'm certain that your analysis will prove invaluable to many, as it provides a comprehensive and engaging overview of ImmuPharma's recent strides and long-term potential. I look forward to more of your contributions. Thank you and GLA! :)
Oscar are you Jabob Rees Mogg lol? I always worry about a placing when people who sound clever start posting
Over at BRES today, the sp went up. After the placing.
Does happen.
Oscar22.
I appreciate your analysis of IMM's strengths and the excellent prospects the company has of success in the use of the P140 platform in treating two autoimmune diseases, Lupus and CIDP.
Another reason (not mentioned by Oscar) to believe in the wide potential of IMM's peptide's platform, is the strength which the company derives from its exclusive right to commercialise the discoveries of France's principal scientific research institute, CNRS. And so, on its scientific team it has Prof. Sylvane Muller, one of the research directors of CNRS, and inventor of P140.
Eventually, and likely within 2 to 3 years, we can expect a further roll-out of the P140 as an effective treatment of other autoimmune diseases such as asthma, which have huge market potential.
Moreover, IMM's link to the CNRS, may ensure that IMM remains true to its mission to bring to market a wide range of treatments based on the P140 platform and prevent it from becoming an easy prey to large pharma companies with deep pockets.
Returning to Oscar's post, it would be a rash person who would contradict his evident confidence that Lupuzor will get FDA approval to proceed to a Phase 2/3 trial on the basis of its protocol and that the trial has a very good prospect of success.
Oscar22 - ROFL. That's all.
Cauldstream7,
You seem to have blown out of all proportions the relationship between IMM and the CNRS …
They are both co owners of the P140 patents whilst IMM has the commercial rights to advance the clinical trials / marketing etc
The CNRS is a major European research institute and the Imm connexion is only one of many thousands of programs in which they participate….
Wow FAB placing at 85% discount!! Thank the lord for Lanstead funding lol
Very strange trading day
Nolupus:
My assessment of the relationship between CNRS and IMM is not overblown. I believe that it is not one of thousands of the same between CNRS and other companies. The agreement for the sharing of patents relating to P140 is of major importance and could have huge implications for the health of millions of sufferers from diseases of the immune system, as well as the earnings of IMM and CNRS through its licensing agreement with IMM for the P140 patents.
Cauldstream7,
The CNRS he nearly 32 000 employees … How many do you think are working on the P140 ?
Put things into perspective -)
Nolupus.
To judge the importance of a scientific discovery by the number of employees involved in the lab and behind-the-scenes work is daft. One Sherlock Holmes is worth a 1000 plods on the beat.
In any case, P140 was discovered around 10 years ago by Prof Sylvane Muller so what does that have to do with current employee numbers at CNRS?
I try not to engage much with him poker'' as i also know his game, only positive when he get his buying price
and IMO, he perhaps sold out 28th APRIL because after that date he started talking about
people that bought sub 2p will be taking some of the table, then his post started to slow down
when we got that surprise RNS, and ever since its been placing in most of his post
and lately seem to be getting desperate enough to follow other trolls to hammer hope placing
but may i remind them that we are fully funded to 2024 and if we was to get some more money
in the coffers it would be from a HNW investor who would want in at a premium to where we are now''
or it will be from our partner Avion who would want a bit more than the 3% they have already
before FDA approval
see what happen in the days ahead, as i suspect we will hold 3p and above quite well
right up to the next FDA meeting that is only days away''
Regards
Cauldstream7,
Prof Muller is your Sherlock Holmes ? Yes she invented the P140/ Lupuzor more than 20 years ago , and so far nothing on the market !!
Without giving away her personal details , she is over seventy so try and keep that in mind